Qibai Pingfei Capsule tied to fewer COPD flare-ups via NK-cell repair
A randomized, double-blind trial links the Chinese herbal formula to reduced exacerbations and better symptom scores, with single-cell sequencing pointing to restored natural killer cell function as the mechanism.
Executive Summary
- A randomized, double-blind, placebo-controlled trial found that a traditional Chinese herbal capsule reduced flare-ups and improved a standard COPD symptom questionnaire, while leaving core lung-function measures unchanged.
- Single-cell sequencing traced the effect to depleted and dysfunctional natural killer cells in COPD patients, and showed the treatment restored NK cell activity through two specific surface receptors, a mechanistic account layered onto the clinical result.
- The result moves a long-used herbal therapy from anecdotal clinical practice toward a testable immunological explanation, while the lack of effect on lung function and walk distance means it does not yet establish a disease-modifying benefit.
The stake
Chronic obstructive pulmonary disease (COPD) involves prolonged inflammation driven by interactions among immune cells, functional lung cells, and inflammatory cytokines. Qibai Pingfei Capsule (QBPF), a traditional Chinese medicine, has been used clinically to treat COPD for more than two decades, but the mechanism behind its effect had not been established with cellular-level evidence. Researchers used single-cell RNA sequencing (scRNA-seq), a technique that profiles gene activity in individual immune cells, to test whether QBPF changes the immune-inflammatory environment that drives the disease. QibaiQibai Pingfei Capsule ameliorates NK‑cell dysfunction in COPD: Insights from single‑cell sequencing in a randomized multicenter double‑blinded placebo‑controlled trial.Jul 20, 2026
How it was done
The trial randomized COPD patients across multiple centers to QBPF or placebo under double-blind conditions. Peripheral blood mononuclear cells from trial participants underwent single-cell sequencing, and researchers combined this with lung-tissue single-cell data from a public repository (GEO: GSE162610). A COPD rat model was used separately to confirm the regulatory mechanism identified in the human samples. Clinical endpoints tracked included acute exacerbation frequency, the COPD Assessment Test (CAT) symptom score, lung function, the 6-minute walk test (6MWT), and the modified Medical Research Council (mMRC) dyspnea scale. QibaiQibai Pingfei Capsule ameliorates NK‑cell dysfunction in COPD: Insights from single‑cell sequencing in a randomized multicenter double‑blinded placebo‑controlled trial.Jul 20, 2026
The clinical result
Acute exacerbation frequency decreased significantly with QBPF treatment (p = 0.042), and CAT scores improved (p = 0.008). Lung function, the 6MWT, and the mMRC scale showed no change against placebo. Within the QBPF group alone, the 6MWT and the ratio of forced expiratory volume to forced vital capacity (FEV1/FVC%) improved from baseline to 3 months (both p < 0.01), a within-group change rather than a placebo-controlled comparison. QibaiQibai Pingfei Capsule ameliorates NK‑cell dysfunction in COPD: Insights from single‑cell sequencing in a randomized multicenter double‑blinded placebo‑controlled trial.Jul 20, 2026
The mechanism
Single-cell sequencing showed immune dysfunction in COPD patients centered on depleted and functionally impaired natural killer (NK) cells. QBPF altered the expression of functional markers on NK cells in treated patients, and the companion rat model confirmed that QBPF increased NK cell activity by modulating two receptors: hepatitis A virus cellular receptor 2 (HAVCR2) and killer cell lectin-like receptor C2 (KLRC2). Both receptors regulate how NK cells recognize and respond to distressed cells, giving the symptom improvement a specific immunological account rather than a general anti-inflammatory one. QibaiQibai Pingfei Capsule ameliorates NK‑cell dysfunction in COPD: Insights from single‑cell sequencing in a randomized multicenter double‑blinded placebo‑controlled trial.Jul 20, 2026
What it means for practice
The pairing of a reduction in exacerbations and CAT score improvement with a defined immune mechanism supports continued clinical use of QBPF in COPD management and gives clinicians a biological rationale beyond long-standing practice. The absence of change in lung function and walk distance means the therapy has not been shown to alter the underlying airflow limitation that defines the disease, only exacerbation frequency and reported symptom burden. QibaiQibai Pingfei Capsule ameliorates NK‑cell dysfunction in COPD: Insights from single‑cell sequencing in a randomized multicenter double‑blinded placebo‑controlled trial.Jul 20, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.